Gastrointestinal stromal tumours
Citations Over TimeTop 1% of 2003 papers
Abstract
The 5-year survival rate after complete resection of GISTs is approximately 50 per cent. The median duration of survival for patients with a metastatic GIST is approximately 20 months, and 9-12 months for patients with local recurrence. Phase II trials have investigated the effect of imatinib on irresectable or metastatic GISTs. In these trials more than 50 per cent of patients responded to imatinib within a few months and approximately 12 per cent had disease progression. Uptake of [(18)F]fluoro-2-deoxy-D-glucose demonstrated by positron emission tomography has been found to be reduced after starting imatinib. The potential for cure and the optimal length of treatment is currently unknown. Imatinib is the first effective systemic therapy for metastatic and locally irresectable GISTs. Large multi-institutional clinical trials to investigate the efficacy of imatinib as adjuvant or neoadjuvant therapy for GISTs are now required.
Related Papers
- → Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients(2003)143 cited
- → The role of imatinib plasma level testing in gastrointestinal stromal tumor(2010)18 cited
- → Gastrointestinal Stromal Tumor (GIST) - Single Center Experience of prolonged treatment with Imatinib(2005)13 cited
- → Imatinib Dose Interruption in GIST: High Progression Risk for 3-YearResponders(2007)
- Research Progress of Imatinib Preoperative Chemotherapy in Treatment of Advanced Gastrointestinal Stromal Tumor(2014)